Given the global burden of heart failure, strategies to understand the underlying cause or to
provide prognostic information are critical to reducing the morbidity and mortality associated …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Patients vary widely in their response to drugs. Having an understanding of the
pharmacokinetic and pharmacodynamic properties of various medications is important when …

Dilated cardiomyopathy (DCM) is a myocardial disease characterized by dilatation and
impaired systolic function of the left or both ventricles. The etiology of DCM is multifactorial …

Importance The prevalence of nonischemic dilated cardiomyopathy (DCM) is greater in
individuals of African ancestry than in individuals of European ancestry. However, little is …

The enduring subdivision of cardiomyopathies into hypertrophic (HCM), dilated (DCM), and
restrictive (RCM) categories reflects the emphasis of traditional classifications on …

BACKGROUND: The angiotensin-converting enzyme (ACE) deletion allele, ACE D, is
associated with increased ACE activity and adverse outcomes in cardiovascular disease …

Anthracyclines are a major component of chemotherapies used in many pediatric and adult
malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse …

Angiotensin (Ang)-converting enzyme (ACE) inhibitors are widely used for the treatment of
cardiovascular diseases. Not all patients respond to ACE inhibitors, and it has been …

The pathogenesis of heart failure involves a complex interaction between genetic and
environmental factors. Genetic factors may influence the susceptibility to the underlying …